Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients

Chest

Volumn 112, Issue 4, 1997, Pages 960-966

  Chen, Yuh Min ^a,c,e   Yang, Wen Kuang ^b,c   Ting, Chou Chik ^d   Tsai, Wen Ying ^a,c   Yang, Den Mei ^b,c   Whang Peng, Jacqueline ^b,c   Perng, Reury Perng ^a,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Interleukin 2 (IL 2); Interferon (IFN )

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 12;

ADENOCARCINOMA; ADOPTIVE IMMUNOTHERAPY; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IMMUNOPHENOTYPING; LUNG CANCER; LYMPHOKINE ACTIVATED KILLER CELL; PLEURA EFFUSION; PRIORITY JOURNAL;

EID: 0030821151     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.112.4.960     Document Type: Article

References (20)

1. Sahn SA. The pleura. Am Rev Respir Dis 1988; 138:184-234
2. Light RW. Pleural diseases. Dis Month 1992; 38:261-331
3. Weissler JC, Nicod LP, Toews GB. Pulmonary natural killer cell activity is reduced in patients with bronchogenic carcinoma. Am Rev Respir Dis 1987; 135:1353-57
4. Inoue Y, Shijulo N, Uede T. Induction of killer cells from lymphocytes in pleural effusion of advanced lung cancer patients. Jpn J Cancer Res 1990; 81:1012-20
5. Blanchard DK, Kavanagh JJ, Sinkovics JG, et al. Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients. Cancer Res 1988; 48:6321-27
6. Chen YM, Yang WK, Whang-Peng J, et al. Elevation of interleukin-10 levels in malignant pleural effusion. Chest 1996; 110:433-36
7. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485-92
8. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin 2 or high dose interleukin 2 alone. N Engl J Med 1987; 316:889-97
9. West WH, Kurt TW, Yannell JR, et al. Constant infusion recombinant interleukin 2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316:898-905
10. + T cells. J Exp Med 1996; 184:19-29
11. Schwartz RH. Models of T cell anergy: is there a common molecular mechanism? J Exp Med 1996; 184:1-8
12. Chehimi J, Trinchieri G. Interleukin-12: a bridge between inmate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol 1994; 14:149-61
13. Gately MK. Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors. Cancer Invest 1993; 11:500-06
14. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84:4008-27
15. Kennedy MK, Picha KS, Shanebeck KD, et al. Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0, clones. Eur J Immunol 1994; 24:2271-78
16. Chouaib S, Chehimi J, Bani L, et al. Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci USA 1994; 91:12659-63
17. Thierfelder WE, van Deursen JM, Yamamoto K, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural and T cells. Nature 1996; 382:171-74
18. Bhardwaj N, Seder KA, Reddy A, et al. IL-12 in conjunction with dendritic cells enhances antiviral CO8+ CTL responses in vitro. J Clin Invest 1996; 98:715-22
19. Wit DD, Flemming CL, Harris JD, et al. IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL). Clin Exp Immunol 1996; 105:353-59
20. Fujiwara H, Hamaoka T. Antitumor and antimetastatic effects of interlenkin-12. Cancer Chemother Pharmacol 1996; 38(suppl):S22-26